Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of $^{18}$F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation

INTRODUCTION

Sarcopenia is defined as the loss of the skeletal muscle mass and function and it is mainly a phenomenon age-related. With ageing, a reduction in the muscle fibre size and number is physiological and causes a loss of the muscle mass of approximately 30%. The causes of sarcopenia are multifactorial and potentially associated with different conditions, such as endocrine dysfunctions, muscle disuses, gender, chronic diseases (like inflammation and nutritional deficiencies) or iatrogenic. The clinical meaning of the sarcopenia is widely recognised, but its definition and correlation coefficient ($r$) was used to correlate measurements from the two imaging modalities.

RESULTS: Comparison of HDCT and LDCT data demonstrated a strong correlation for measurement of VAT ($r = 0.942$, $p < 0.0001$), SAT ($r = 0.894$, $p < 0.0001$) and SMA ($r = 0.934$, $p < 0.0001$). Instead considering IMAT, correlation was good but less significant ($r = 0.742$). The mean difference between the two methods was found to be very small, with a difference of 1% for SAT, +6.1% for VAT, +2.5% for SMA and −1.9% for IMAT.

CONCLUSION: LDCT of PET/CT is a safe, accurate and precise method for the measurements of skeletal muscle area, visceral and subcutaneous adipose tissue. Their measurements are reproducible and correlate closely with HDCT.

Advances in knowledge: LLDCT of PET/CT is a safe and accurate alternative tool for measuring abdominal fat and muscles in the clinical practice.
radiological assessment method are still under discussion. Early attempts to define the sarcopenia were based on the measurements of the skeletal muscle mass with dual energy X-ray absorptiometry (DXA) in relation to the body size, but they presented significant limitations; e.g. DXA is unable to evaluate the intramuscular fat, which can account for 5–15% of observed muscle mass. High-dose CT (HDCT) is a tool frequently used in oncological patients for the staging or restaging purposes and it may be used to assess the total and fat-free muscle area, with a smaller risk of error than that compared to DXA. MRI has a similar accuracy and reproducibility for the fat and muscle measurements and may be used also for a whole-body imaging study. Both CT and MRI can be able to discriminate tissue compartments in the abdomen with a good accuracy. The segmentation analysis of a single axial CT image at the third lumbar vertebra (L3) is a reference method for the body composition assessment, particularly in the oncological setting. The advantages of CT are its wide availability, its relative low cost and its speed. For these reasons, CT is recognised as one of most reliable methods for the in-vivo quantification of the body composition, while MRI has been increasingly adopted in this field due to radiation exposure concerns as well as the potential to achieve improved tissue contrast.

The clinical and prognostic role of the sarcopenia has already been demonstrated in several oncological diseases and an important clinical impact was also reported for lymphoma patients. Although studies based on Hodgkin lymphoma (HL) are so far rare.

Fluorine-18-fludeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) is a non-invasive tool with proven usefulness in the evaluation of HL in the staging, treatment response evaluation and prognosis. There are also several studies showing the important role of 18F-FDG-PET/CT in elderly patients.

The CT part of a PET/CT system is not always a contrast-enhanced HDCT due to the fact that the main aims are to provide precise anatomical localisation of radiotracer uptake identified on the PET images and the attenuation correction of the PET emission data. To reach this target also a low-dose CT (LDCT) may be sufficient and some centres opt for this system to reduce radiation exposure to the patients.

However, no studies to our knowledge have compared the measurements of the abdominal skeletal muscle area and adipose tissue areas between these two modalities (HDCT and LDCT of PET).

The purpose of this bicentric retrospective study was to investigate the agreement and correlation between HDCT and LDCT of PET measurements of the adipose tissue and skeletal muscle area in elderly HL.

**METHODS AND MATERIALS**

**Patients**

In this retrospective study, 90 patients with newly diagnosed histologically proven HL were selected consecutively from the institutional electronic patient health record of two tertiary care centres between January 2010 and December 2019 (66 patients from one centre and the remaining 24 form the other). The main features of our population are summarised in Table 1. All patients performed both a whole body 18F-FDG PET/CT and a high-dose thoracic-abdominal CT within a maximum interval of 10 days (median 5, range 1–10 days).

**18F-FDG PET/CT imaging**

The 18F-FDG PET/CT acquisition was performed according to the standard operating procedures, after at least 6h fasting and with blood glucose levels < 150mgdl−1. An activity of 3.5 MBq/kg was administered intravenously (mean activity injected 245 MBq, range 161–315 MBq) and the imaging was acquired 60min after injection from the skull base to the mid-thigh (2.5 min per bed; steps of 15 cm), using a Discovery ST-E (D-STE) or 690 (D-690) scanner (General Electric, Milwaukee, WI) or on a Biograph True Point PET/CT tomograph (Siemens Medical Solutions, Erlangen, Germany). For all scanners, a standard non-contrast free-breathing helical LDCT was obtained for morphologic correlation and attenuation correction. The D-STE acquisition parameters were: 120 kV, fixed tube current ~73 mAs (40–160 mAs), eight slices × 3.75 mm and 3.27 mm interval, pitch 1.5, tube rotation 0.8 s. The D-690 and Biograph True Point acquisition parameters were: 120kV, fixed tube current ~60 mAs (40–100 mAs), 64 slices × 3.75 mm and 3.27 mm interval, pitch 0.984:1, tube rotation 0.5 s. The PET/CT images were reconstructed using a 512 × 512 matrix and iterative reconstruction, 3.75 mm slice thickness and 3.25 mm interval, standard filter with a window setting with 400 Hounsfield units (HUs) of window width and 40 HU of window level. Patients were instructed to

| **Table 1. Baseline features of our population** |
| **Patients n (%)** |
| **Age years mean ± SD (range)** | 72.2 ± 5 (65–85) |
| **Sex male** | 45 (50%) |
| **Sex female** | 45 (50%) |
| **Tumour stage at diagnosis (Ann Arbor)** |
| **I** | 4 (4%) |
| **II** | 21 (24%) |
| **III** | 30 (33%) |
| **IV** | 35 (39%) |
| **BMI > 25** | 34 (38%) |
| **B symptoms** | 43 (48%) |
| **Bulky disease** | 9 (10%) |
| **LDH ≤245** | 49 (54%) |
| **>245** | 41 (46%) |
| **Bulky disease** | 9 (10%) |
| **Histotype: classic** | 59 (66%) |

BMI, Body mass index; HDCT, High-dose CT; IMAT, Intramuscular adipose tissue; LDCT, Low-dose CT; LDH, Lactate dehydrogenase; SAT, Subcutaneous adipose tissue; SD, Standard deviation; SMA, Skeletal muscle area; VAT, Visceral adipose tissue.
void before imaging acquisition, no oral or intravenous contrast agents were administrated or bowel preparation used for any patient; written consent was obtained before studies.

CT imaging
HDCT scans were performed on 15 different scanners of 4 different CT manufacturers: 5 General Electric scanners (a Brightspeed, a Lightspeed Plus, a Lightspeed VCT, a Optima CT520 series, and a Optima CT660), 5 Siemens scanners (a Somatom Definition Flash, a Sensation 16 and a Scope), 2 Toshiba scanner (a Aquilion and a Asteion), and 2 Philips scanner (a Brilliance 64 and a Brilliance 16). The acquisition parameters were: tube voltage settings were selected 100, 120 and 130 kV and tube current in a range of values from 65 to 389 mAs (mean 150). The CT images were reconstructed using a 512 × 512 matrix and standard filter. Contrast enhancements venous phase images were used for the measurements in 35 examinations, while in the remaining 55 cases not-enhanced images were selected. The main technical features are resumed in Supplementary Table 1.

Imaging analysis
HDCT and LDCT images were analysed by two researchers (DA, AC) for the measurements of the adipose and muscular tissues using Slice-O-Matic software v. 4.2 (Montreal, Quebec, Canada Tomovision). Each researcher analysed the images of scans performed in his centre.

An axial section with a multiplanar reconstruction at third lumbar vertebra was used to measure the skeletal muscle area (SMA) considering psoas, paraspinal, abdominal transverse rectum, internal and external obliques and visceral, subcutaneous and intramuscular adipose tissue (VAT, SAT, IMAT). CT HU thresholds were -29 to 150 for SMA, -190 to -30 for SAT, -190 to -30 IMAT, and -50 to -150 for VAT. The tissue margins were manually corrected as needed.

A second observer (RR) of one centre made the muscular and adipose areas measurements randomly in 45 patients (both HDCT and LDCT scans) already evaluated by another researcher in order to calculate the interobserver variability.

Table 2. Interobserver agreement for the evaluation of SMA, VAT, SAT and IMAT in 45 patients

|            | HDCT Observer 1 | Observer 2 | ICC     |
|------------|-----------------|------------|---------|
| SMA (cm²) mean ± SD | 112.4 ± 29      | 114.9 ± 30.3 | 0.936   |
| VAT (cm²) mean ± SD | 145 ± 85        | 139.9 ± 74  | 0.929   |
| SAT (cm²) mean ± SD | 149.9 ± 63.2    | 150.7 ± 65  | 0.940   |
| IMAT (cm²) mean ± SD | 16.8 ± 10.6     | 15.4 ± 10.2 | 0.924   |
| LDCT Observer 1 | 113.2 ± 25.5    | 114.2 ± 23.9 | 0.959   |
| Observer 2 | 139.4 ± 84.2    | 140.9 ± 85.5 | 0.955   |
| SAT (cm²) mean ± SD | 144.5 ± 71      | 146 ± 72.2  | 0.933   |
| IMAT (cm²) mean ± SD | 18.9 ± 13.8     | 17.4 ± 12.8 | 0.909   |

HDCT, High-dose computed tomography; ICC, Intraclass coefficient correlation; IMAT, Intramuscular adipose tissue; LDCT, Low-dose computed tomography; SAT, Subcutaneous adipose tissue; SMA, Skeletal muscle area; VAT, Visceral adipose tissue.
The Passing-Bablock regression analysis for each center demonstrated similar results with the exception of IMAT, where the measurements were significantly different (Table 3).

**Table 3.** Correlation analysis between HDCT and LDCT (n = 90)

|                      | All population (n 90) |          |          |          |
|----------------------|-----------------------|----------|----------|----------|
|                      | HDCT                  | LDCT     | Correlation coefficient | p-value  |
| SMA (cm²) mean ± SD (range) | 114.4 ± 29 (60-188) | 111.9 ± 31 (49.9–192) | 0.919 | <0.001   |
| VAT (cm²) mean ± SD (range) | 143.4 ± 87 (17.1–368) | 137.3 ±83 (5–422) | 0.941 | <0.001   |
| SAT (cm²) mean ± SD (range) | 149.9 ± 67.9 (47–444) | 149 ± 71.3 (14.5–448) | 0.901 | <0.001   |
| IMAT (cm²) mean ± SD (range) | 17.1 ± 12.6 (1.2–95.7) | 19 ± 15.6 (1–99) | 0.749 | <0.001   |

|                      | Centre n°1 (n 66)    |          |          |          |
|                      | HDCT                  | LDCT     | Correlation coefficient | p-value  |
| SMA (cm²) mean ± SD (range) | 113.9 ± 27.6 (66.8–188) | 115 ± 28.8 (68–192) | 0.971 | <0.001   |
| VAT (cm²) mean ± SD (range) | 142.3 ± 86.8 (17.1–368) | 139.8 ±83.9 (5–422) | 0.942 | <0.001   |
| SAT (cm²) mean ± SD (range) | 155.1 ± 67.5 (47–444) | 155.6 ± 71.7 (14.5–448) | 0.945 | <0.001   |
| IMAT (cm²) mean ± SD (range) | 17.8 ± 14.1 (1.2–95.7) | 20.5 ± 17.4 (1–99) | 0.939 | <0.001   |

|                      | Centre n°2 (n 24)    |          |          |          |
|                      | HDCT                  | LDCT     | Correlation coefficient | p-value  |
| SMA (cm²) mean ± SD (range) | 115.8 ± 33.3 (60–176.8) | 103.8 ± 35.8 (49.9–170) | 0.888 | <0.001   |
| VAT (cm²) mean ± SD (range) | 146.2 ± 89.7 (17.2–389) | 130.7 ± 82.6 (11.9–341) | 0.967 | <0.001   |
| SAT (cm²) mean ± SD (range) | 136.3 ± 68.5 (27.8–317) | 131.4 ± 68.4 (30.5–297) | 0.911 | <0.001   |
| IMAT (cm²) mean ± SD (range) | 15.1 ± 7.2 (2.5–31.7) | 15.1 ± 8.6 (3.6–33.4) | 0.570 | 0.004    |

HDCT, High-dose computed tomography; IMAT, intramuscular adipose tissue; LDCT, Low-dose CT; SAT, Subcutaneous adipose tissue; SMA, Skeletal muscle area; VAT, Visceral adipose tissue.
Applying Bland–Altman analysis, the mean difference between the two methods was small (Figure 3), with a value of 2.5% for SMA, +6.1% for VAT, 1% for SAT and −1.9% for IMAT but with wide limits of agreement especially for VAT (limits of agreement −50.8% to +63.1%) e SAT (limits of agreement −62.1% to +64.31%) and moderate for SMA (limits of agreement −19.3% to +24.3%) and IMAT (limits of agreement −22.5% to +18.7%).
DISCUSSION

Our analysis showed a good inter- and intraobserver agreement for the measurements of SMA, VAT and SAT between the HDCT and LDCT images; only for IMAT both the inter- and the intraobserver agreement were less significant and reproducible. Moreover, a significant difference between the two centres in IMAT measurements was registered, while for other factors the agreement was good. These evidences are well showed considering Figure 1 and Table 3; for IMAT measurements there were some cases markedly different between HDCT and LDCT. This discrepancy may be explained by the low area of adipose tissue present usually between muscular fibres (average value lower than SAT and VAT). Therefore, also a minimal difference (as a possible error operator-dependent) in the measurements may be expressed as a statistically significant difference. Moreover, the detection and the measurement of IMAT is technically challenging in comparison with the other parameters especially due to the difficulties to recognize safely the muscular margins. For this reason, among our parameters, we may certainly support the idea that the IMAT analysis is the most difficult and less reproducible. For the other variables (SAT, VAT, SMA), a less number of discordant cases was described, except of one patient where there was a significantly high difference in the SAT evaluation probably related to an operator-dependent error.

Passing–Bablok regression analysis showed no systematic differences and no proportional differences for all parameters (for SMA intercept of 7.337, 95% CI −1.805 to 13.547; slope of 0.937, 95% CI 0.883 to 0.991; for VAT intercept of 0.793 95% CI −9.315 to 9.001; slope of 1.045, 95% CI 0.974 to 1.124; for SAT intercept of 9.129, 95% CI −2.439 to 17.314; slope of 0.927, 95% CI 0.862 to 1.001), except of proportional difference for IMAT (intercept of 0.769, 95% CI −0.203 to 2.306; slope of 0.900, 95% CI 0.809 to 0.971). Applying Passing Bablok regression analysis, we demonstrated that the constant and proportional bias between the two methods were not significant with the exception of IMAT.

Also applying the Bland–Altman analysis, that is a statistical method utilised in the assessment of difference in measurement techniques, we found a very small difference considering the mean value between the body estimates utilising HDCT and LDCT, ranging from −1.9 to 6%. Instead observing 95% limits of agreement for VAT and SAT comparison, the differences were high (>60%), indicating that large intervals in measurements were present. The effective clinical meaning of these wide intervals needs to be clarify and could be potentially affected by the relatively low sample analysed. This evidence reduce the effective positive agreement derived by Bland–Altman analysis. Instead for IMAT and SMA, the differences were lower despite the 95% limits of agreement remained quite high underlying that the two methods were relatively equivalent for the measurement of these factors.

Thus, these preliminary results reflect the potential reproducibility of these two techniques suggesting a possible role of LDCT in estimating the muscular and adipose areas, despite the high agreement and reproducibility was not achieved.

A crucial point derived from our study, is that the abdominal muscular and adipose tissue areas can be measured with high accuracy also by LDCT of PET/CT. CT of PET/CT may be a LDCT because usually doesn’t have strictly a diagnostic role. Its main roles are the attenuation correction and the anatomical localisation, which are crucial for the evaluation and quantification of PET images and improve the diagnostic performance.

Another potential usefulness to study the accuracy of LDCT in measuring these parameters is the situation when the patients performed HDCT in a different centre compared to PET/CT scan with the risk that electronic images of one these two examinations are not always available due to the local policies and/or organisational issues. In this case, the measurements of muscular and adipose areas could be done with the tool available.

The potential impact of the contrast enhancement in the measurements of the body parameters is not yet clear with only few reports present in literature but with controversial results. Boutin et al28 demonstrated that the contrast injection influenced the skeletal muscle and bone changing attenuation value, but they also showed that the contrast enhancement may vary significantly with age, gender, and unenhanced tissue attenuation and, in the case of muscle, by anatomic region.

In our analysis, we preferred to use unenhanced images of HDCT for the comparison of the muscular and adipose areas with LDCT if possible (n = 55) and we utilised the contrast-enhanced venous phase HDCT images as alternative (n = 35), but we derived a high correlation for both kind of images. This evidence underlies the concept that the contrast enhancement could not affect significantly this kind of measurements.

Other authors found an excellent agreement between non-contrast and contrast SMA measurements29 or a not clinically relevant differences in skeletal muscle mass measurements.30 In contrast, Feng et al31 observed a significant difference between the unenhanced and arterial and venous phases. In our analysis, we didn’t find any differences using unenhanced and enhanced phases of HDCT; the correlation and the agreement with LDCT is not significantly different and is high in all cases. Instead for the subcutaneous or visceral adipose tissues, no comparison between not-enhanced and enhanced images are available.

Unlike other papers that included heterogeneous populations,28–31 one of the strength of our paper is the fact that we studied a specific population: all elderly patients affected by HL.

For the study of HL, 18F-FDG PET/CT has a crucial role both in the staging and evaluation of treatment response fields.22 Recent evidences have suggested a possible clinical and prognostic role of sarcopenia in lymphoma,15–21 especially in elderly patients. We can intrinsically consider SMA as a part of the diagnostic definition of sarcopenia, then its measurement appears crucial and we need a feasible and validated method. 18F-FDG PET/CT is usually used for the evaluation of metabolic behaviour and FDG-avidity of lymphoma; adding also a body composition
analysis (particularly SAT, VAT and SMA) can make this evaluation more complete and solid.

Nowadays, the body composition analysis (like the measurements of muscular and adipose areas) is not routinely diffuse in clinical practice due to the not shared clinical meaning and the lack of time-efficient and clinical-friendly assessment tools that could allow accurate muscle and adipose tissue measurements. The analysis of CT images requires specific segmentation of different tissue areas which can be not easy. Several semi-automated software for the analysis of body composition from medical imaging are available, like Slice O-Matic, but most of these methods have not been externally evaluated in large, real-world data sets.

For this reason, the research of an automated system to estimate the body composition can be crucial with the aim to reduce the workload and to accelerate the research in the body composition and chronic disease outcomes by leveraging the vast repositories of imaging data available within health systems. The demonstration of a good accuracy and the validation of LDCT in the measurements of the adopenic and muscular areas as a surrogate of sarcopenia may have several clinical advantages such as the possibility to have both metabolic and morphological information from the same tool (PET/CT), the reduced radiation exposure and the immediacy of sarcopaenic measurements after scan.

Despite further studies are needed to confirm or controvert our findings, these measurements may help to change early the patient’s management or better stratify the clinical features of the patients.

The limitations of our study are the retrospective nature of the study design, the heterogeneity of CT scanner and protocols used (with or without enahnced-contrast) and the relatively low number of patients analysed, also due to the rarity of the disease. Another limitation is the interobserver agreement evaluated only in half of the population included. Despite this, so far, the present study represents the first series of elderly HL in which HDCT and LDCT were compared in the measurement of the skeletal muscles and adipose tissues.

In conclusion, LDCT of PET/CT is a safe, accurate and precise method for the measurements of the skeletal muscle area, visceral and subcutaneous adipose tissue. Their measurements are reproducible and correlate closely with HDCT imaging. Compared with HDCT, LDCT is a possible accurate alternative for measuring abdominal fat and muscles in clinical practice.

INFORMED CONSENT
Informed consent was obtained from all individual participant included in the study.

ETHICS APPROVAL
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

REFERENCES
1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16–31. doi: https://doi.org/10.1093/ageing/afy169
2. Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ, Roubenoff R. Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol 2000; 88: 1321–6. doi: https://doi.org/10.1152/japp.2000.88.4.1321
3. Lexell J, Taylor CC, Sjöström M. What is the cause of the ageing atrophy? total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci 1988; 84(2-3): 275–94. doi: https://doi.org/10.1016/0022-510x(88)90132-3
4. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB. International Working group on sarcopenia. sarcopenia: an -undiagnosed condition in older adults current consensus definition: prevalence, etiology, and consequences. J Am Med Dir Assoc 2011; 12: 249–56.
5. Plank LD. Dual-Energy X-ray absorptionometry and body composition. Curr Opin Clin Nutr Metab Care 2005; 8: 305–9. doi: https://doi.org/10.1097/01.mco.0000165010.31826.3d
6. Hansen RD, Williamson DA, Finnegam TP, Lloyd BD, Grady JN, Diamond TH, et al. Estimation of thigh muscle cross-sectional area by dual-energy X-ray absorptiometry in frail elderly patients. Am J Clin Nutr 2007; 86: 952–8. doi: https://doi.org/10.1093/ajcn/86.4.952
7. Cooper C, Fielding R, Visser M, van Loon LJ, Rolland Y, Orwoll E, et al. Tools in the assessment of sarcopenia. Calcif Tissue Int 2013; 93: 201–10. doi: https://doi.org/10.1007/s00223-013-9757-z
8. Sinelnikov A, Qu C, Fetzer DT, Pelletier J-S, Dunn MA, Tsung A, et al. Measurement of skeletal muscle area: comparison of CT and MR imaging. Eur J Radiol 2016; 85: 1716–21. doi: https://doi.org/10.1016/j.ejrad.2016.07.006
9. Klopfenstein BJ, Kim MS, Krisky CM, Szumowski I, Rooney WD, Purnell JQ. Comparison of 3 T MRI and CT for the measurement of visceral and subcutaneous adipose tissue in humans. Br J Radiol 2012; 85: e826–30. doi: https://doi.org/10.1259/bjr/57987644
10. Lee SJ, Jansen I, Heymsfield SB, Ross R. Relation between whole-body and regional measures of human skeletal muscle. Am J Clin Nutr 2004; 80: 215–1221. doi: https://doi.org/10.1093/ajcn/80.5.1215
11. Shen W, Punyanitya M, Wang Z, Gallagher D, St.-Onge M-P, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004; 97: 2333–8. doi: https://doi.org/10.1152/japplphysiol.00744.2004
12. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al.
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *Lancet Oncol* 2008; 9: 629–35. doi: https://doi.org/10.1016/S1470-2045(08)70153-0

13. Fearon K, Strasser F, Anker SD, Bosaues I, Brueru E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011; 12: 489–95. doi: https://doi.org/10.1016/S1470-2045(10)70218-7

14. Fosbøl Marie Ø., Zerahn B. Contemporary methods of body composition measurement. *Clin Physiol Funct Imaging* 2015; 35: 81–97. doi: https://doi.org/10.1111/cpf.12152

15. Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. *Ann Hematol* 2015; 94: 2043–53. doi: https://doi.org/10.1007/s00277-015-2499-4

16. Lanic H, Kraut-Tauzia J, Modzeleowski R, Clotot F, Mareschal S, Picquenot JM, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Leuk Lymphoma* 2014; 55: 817–23. doi: https://doi.org/10.3109/10428194.2013.816421

17. Jabbour J, Manana B, Zahreddine A, Saade C, Charafeddine M, Bazarbachi A, et al. Sarcopenic obesity derived from PET/CT predicts mortality in lymphoma patients undergoing hematopoietic stem cell transplantation. *Curr Res Transl Med* 2018; 67: 93–9. doi: https://doi.org/10.1016/j.retram.2018.12.001

18. Go S-I, Park MJ, Song H-N, Kim H-G, Kang MH, Lee HR, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. *J Cachexia Sarcopenia Muscle* 2016; 7: 567–76. doi: https://doi.org/10.1002/jcsm.12115

19. Chu MP, Lieffers J, Ghosh S, Belch A, Chua NS, Fontaine A, et al. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. *J Cachexia Sarcopenia Muscle* 2017; 8: 298–304. doi: https://doi.org/10.1002/jcsm.12161

20. Camus V, Lanic H, Kraut J, Modzeleowski R, Clotot F, Picquenot JM, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Eur J Haematol* 2014; 93: 9–18. doi: https://doi.org/10.1111/ejh.12285

21. Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, et al. Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. *Br J Haematol* 2019; 186: 45–53. doi: https://doi.org/10.1111/bjh.15889

22. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014; 32: 3059–67. doi: https://doi.org/10.1200/JCO.2013.54.8800

23. Barrington SF, Mikhael NG, Kostakoglu L, Meignan M, Hutchings M, Müller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on malignant lymphomas imaging Working group. *J Clin Oncol* 2014; 32: 3048–58. doi: https://doi.org/10.1200/JCO.2013.53.5229

24. Albano D, Mazzoletti A, Spallino M, Muzi C, Zilioli VR, Pagani C, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. *Ann Hematol* 2020; 99: 1321–30. doi: https://doi.org/10.1007/s00277-020-04039-w

25. Albano D, Mazzoletti A, Zilioli VR, Muzi C, Crucitti L, Tucci A, et al. Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience. *Leuk Lymphoma* 2020; 61: 3209–16. doi: https://doi.org/10.1080/10428194.2020.1797012

26. Boelhaar R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging* 2015; 42: 328–54. doi: https://doi.org/10.1007/s00259-014-2961-x

27. Xia T, Alessio AM, De Man B, Manjeshwar R, Asma E, Kinahan PE. Ultra-Low dose CT attenuation correction for PET/CT. *Phys Med Biol* 2012; 57: 309–28. doi: https://doi.org/10.1088/0031-9155/57/2/309

28. Boutin RD, Kaptchuk JM, Bateni CP, Chalfant JS, Yao L. Influence of IV contrast administration on CT measures of muscle and bone attenuation: implications for sarcopenia and osteoporosis evaluation. *AJR Am J Roentgenol* 2016; 207: 1046–54. doi: https://doi.org/10.2214/ajr.16.16387

29. van der Werf A, Dekker IM, Meijerink MR, Wiersma NJ, de van der Schueren MAE, Langius JAE. Skeletal muscle analyses: agreement between non-contrast and contrast CT scan measurements of skeletal muscle area and mean muscle attenuation. *Clin Physiol Funct Imaging* 2018; 38: 366–72. doi: https://doi.org/10.1111/cpf.12423

30. van Vugt JLA, Coebergh van den Braak RRJ, Schippers HJW, Veen KM, Levolger S, de Bruin RWE, et al. Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography. *Clin Nutr* 2018; 37: 1707–14. doi: https://doi.org/10.1016/j.clnu.2017.07.007

31. Feng Z, Rong P, Luo M, Sun X, Wang W. Influence of methods used to establish sarcopenia cutoff values for skeletal muscle measures using unenhanced and contrast-enhanced computed tomography images. *JPEN J Parenter Enteral Nutr* 2019; 43: 1028–36. doi: https://doi.org/10.1002/jpen.1519

32. Cespedes Feliciano EM, Popuri K, Cobzas D, Baracos VE, Beg MF, Khan AD, et al. Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients. *J Cachexia Sarcopenia Muscle* 2020; 11: 1258–69. doi: https://doi.org/10.1002/jcsm.12573